Completed
Multimodal therapy approaches (i.e., combinations of interventions aimed at different aspects of a disease) are emerging as potential ways to enhance clinical outcomes for patients with psychiatric and neurological disorders.The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 14-15, 2016 that brought together key stakeholders to examine scientific, clinical, regulatory, and reimbursement issues related to multimodal approaches and identify potential opportunities to enhance clinical outcomes for individuals with nervous system disorders.
Featured publication
Workshop
·2017
Multimodal therapy approaches that combine interventions aimed at different aspects of disease are emerging as potential—and perhaps essential—ways to enhance clinical outcomes for patients with psychiatric and neurological disorders. In order to examine the general principles underlying multimodal...
View details
Description
An ad hoc committee will plan and conduct a 1.5-day public workshop to explore multimodal therapeutic approaches for nervous system disorders (i.e., combinations of interventions aimed at different aspects of a disease). This could include, for example, a drug prescribed along with a device, psychosocial intervention, lifestyle adjustment, or dietary intervention. The workshop will bring together key stakeholders to examine scientific, clinical, regulatory, and reimbursement issues related to multimodal approaches and identify potential opportunities to enhance clinical outcomes for individuals with nervous system disorders.
Invited presentations and discussions will be designed to:
- Explore recent advances in the development of multimodal therapeutic approaches for nervous system disorders and approaches to using these therapies (e.g., earlier versus later in disease progression), and discuss future research needs to further advance understanding of these approaches.
- Highlight disease areas in which a multimodal approach could be particularly useful (e.g., areas in which the pathophysiology is well understood).
- Discuss methodologies for establishing efficacy for multimodal therapies compared to monotherapies, including clinical and statistical considerations.
- Consider regulatory issues for multimodal therapies, including for approaches in which only one component is regulated (e.g., drug plus psychosocial intervention), and discuss potential opportunities for addressing challenges.
- Consider reimbursement issues for multimodal therapies for nervous system disorders, and discuss potential opportunities for addressing challenges.
- Incorporate lessons learned from other therapeutic areas in which multimodal approaches are more frequently used (e.g., diabetes, HIV, cancer).
The committee will develop the agenda for the workshop, select and invite speakers and discussants, and moderate the discussions. A summary of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
Collaborators
Committee
Karl Kieburtz
Co-Chair
Sarah H. Lisanby
Co-Chair
Robert C. Alexander
Member
Timothy Denison
Member
James A. Hendrix
Member
Thinh Nguyen
Member
David Shurtleff
Member
Timothy J. Strauman
Member
Stevin H. Zorn
Member
Sponsors
Department of Health and Human Services
National Science Foundation
Staff
Clare Stroud
Lead
Sheena Posey Norris
Major units and sub-units
Institute of Medicine
Lead
Board on Health Sciences Policy
Lead